A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy
Felip, E Brunsvig, P Vinolas, N Aix, SP Costa, EC Gomez, MD Perez, JMT Arriola, E Campelo, RG Spicer, JF
Felip, E
Brunsvig, P
Vinolas, N
Aix, SP
Costa, EC
Gomez, MD
Perez, JMT
Arriola, E
Campelo, RG
Spicer, JF
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Felip E, Brunsvig P, Vinolas N, Aix S, Costa E, Gomez M, et al. A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. J Clin Oncol. 2019;37(15).